mutations provided The reality that, as described under, CLL therapy relies within the existence or absence of such mutations. The existing consensus is always that, aside from clonal mutations, subclonal mutations having a variant allelic frequency ranging from five to 10% (and therefore under the edge of detection by conventional molecular strate